Viscosupplementation Market Size, Share & Trends Analysis Report By Product (Single Injection, Three Injection, Five Injection), By End-use (Hospitals, Orthopedic Clinics/ASCs), By Region (Asia Pacific, Europe), And Segment Forecasts, 2023 - 2030

Research Methodology

A three-pronged approach was followed for deducing the viscosupplementation market estimates and forecasts. The process has three steps: information procurement, analysis, and validation. The whole process is cyclical, and steps repeat until the estimates are validated. The three steps are explained in detail below:

Information procurement: Information procurement is one of the most extensive and important stages in our research process, and quality data is critical for accurate analysis. We followed a multi-channel data collection process for viscosupplementation market to gather the most reliable and current information possible.

• We buy access to paid databases such as Hoover’s and Factiva for company financials, industry information, white papers, industry journals, SME journals, and more.
• We tap into Grand View’s proprietary database of data points and insights from active and archived monitoring and reporting.
• We conduct primary research with industry experts through questionnaires and one-on-one phone interviews.
• We pull from reliable secondary sources such as white papers and government statistics, published by organizations like WHO, NGOs, World Bank, etc., Key Opinion Leaders (KoL) publications, company filings, investor documents, and more.
• We purchase and review investor analyst reports, broker reports, academic commentary, government quotes, and wealth management publications for insightful third-party perspectives.

Analysis: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilized different methods of viscosupplementation market data depending on the type of information we’re trying to uncover in our research.

• Market Research Efforts: Bottom-up Approach for estimating and forecasting demand size and opportunity, top-down Approach for new product forecasting and penetration, and combined approach of both Bottom-up and Top-down for full coverage analysis.

• Value-Chain-Based Sizing & Forecasting: Supply-side estimates for understanding potential revenue through competitive benchmarking, forecasting, and penetration modeling.

• Demand-side estimates for identifying parent and ancillary markets, segment modeling, and heuristic forecasting.

• Qualitative Functional Deployment (QFD) Modelling for market share assessment.

Market formulation and validation: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilize different methods of data analysis depending on the type of information we’re trying to uncover in our research.

• Market Formulation: This step involves the finalization of market numbers. This step on an internal level is designed to manage outputs from the Data Analysis step.

• Data Normalization: The final market estimates and forecasts are then aligned and sent to industry experts, in-panel quality control managers for validation.

• This step also entails the finalization of the report scope and data representation pattern.

• Validation: The process entails multiple levels of validation. All these steps run in parallel, and the study is forwarded for publishing only if all three levels render validated results.

Viscosupplementation Market Categorization:

The viscosupplementation market was categorized into three segments, namely product (Single Injection, Three Injection, Five Injection), end-use (Hospitals, Orthopedic Clinics/ASCs), and regions (North America, Europe, Asia Pacific, Latin America, Middle East & Africa).

Segment Market Methodology:

The viscosupplementation market was segmented into product, end-use, and regions. The demand at a segment level was deduced using a funnel method. Concepts like the TAM, SAM, SOM, etc., were put into practice to understand the demand. We at GVR deploy three methods to deduce market estimates and determine forecasts. These methods are explained below:

Market research approaches: Bottom-up

• Demand estimation of each product across countries/regions summed up to from the total market.

• Variable analysis for demand forecast.

• Demand estimation via analyzing paid database, and company financials either via annual reports or paid database.

• Primary interviews for data revalidation and insight collection.

Market research approaches: Top-down

• Used extensively for new product forecasting or analyzing penetration levels.

• Tool used invoice product flow and penetration models Use of regression multi-variant analysis for forecasting Involves extensive use of paid and public databases.

• Primary interviews and vendor-based primary research for variable impact analysis.

Market research approaches: Combined

• This is the most common method. We apply concepts from both the top-down and bottom-up approaches to arrive at a viable conclusion.

Regional Market Methodology:

The viscosupplementation market was analyzed at a regional level. The global was divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, keeping in focus variables like consumption patterns, export-import regulations, consumer expectations, etc. These regions were further divided into twenty-three countries, namely, the U.S.; Canada; the UK; France; Germany; Italy; Spain; Sweden; Denmark; Norway; China; Japan; India; South Korea; Australia; Thailand; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait.

All three above-mentioned market research methodologies were applied to arrive at regional-level conclusions. The regions were then summed up to form the global market.

Viscosupplementation market companies & financials:

The viscosupplementation market was analyzed via companies operating in the sector. Analyzing these companies and cross-referencing them to the demand equation helped us validate our assumptions and conclusions. Key market players analyzed include:

• SANOFI - Sanofi, a multinational conglomerate based in France, is actively engaged in the manufacturing, marketing, and research and development of healthcare products. With a global presence, the company operates in approximately 100 countries, utilizing its offices, research and production centers, and logistics services. Sanofi's extensive product portfolio encompasses consumer healthcare products, insulin, generic drugs, enzymes, syrups, tablets, and therapeutic solutions aimed at treating various diseases such as diabetes, cancer, multiple sclerosis, and animal health-related ailments. The company boasts a vast network of 300 subsidiaries worldwide, including notable entities like Aventis, Inc., Aventis Pharma SA, Genzyme Corporation, and Hoechst GmbH. In 2011, Sanofi transferred the commercial rights for the marketing and distribution of its orthopedic product, HYALGAN, to Fidia Farmaceutici S.p.A.

• ANIKA THERAPEUTICS, INC. - Anika Therapeutics, Inc. is a renowned global medical technology company that specializes in the manufacturing, development, and commercialization of HA-based products. Alongside this, the company also manufactures and commercializes products related to orthopedics, ophthalmology, surgical antiadhesives, veterinary osteoarthritis therapies, and dermatology. In 2015, Anika Therapeutics successfully introduced its viscosupplement product, CINGAL, to the U.S. market through direct sales. The company holds exclusive patents for modifying the hyaluronic acid molecule, showcasing its innovative approach. Furthermore, Anika Therapeutics has an impressive pipeline of orthobiologics products, including HYLOFAST (U.S.), MONOVISC (U.S.-HIP), TENDINOPATHY, and CINGAL (U.S.).

• SEIKAGAKU CORPORATION - The organization primarily focuses on the production and distribution of pharmaceuticals and medical devices, with a specific emphasis on glycoconjugates. It operates two main divisions: pharmaceuticals and Limulus Amebocyte Lysate (LAL). Instead of maintaining a sales force, the company relies on sales partners to distribute its products. Currently, the company is developing HA-NSAID conjugates as part of its product pipeline. In terms of financial allocation, approximately 20% of net sales are dedicated to research and development expenditures, highlighting the company's research-oriented nature.

• ZIMMER BIOMET - Zimmer Biomet is a publicly traded company that specializes in providing medical devices for musculoskeletal healthcare. The company designs and markets orthopedic products, craniomaxillofacial & thoracic products, sports medicine, biologics, dental implants, and extremity & trauma products. With a global reach, Zimmer Biomet operates in over 100 countries and generates 40% of its total sales from international markets. The company utilizes three channels to market and sell its products: direct to healthcare organizations, stocking distributors & dealers, and straightforward to dental practices. Originally a division of Bristol Myers Squibb, Zimmer Biomet became an independent entity in 2001. In June 2015, it completed the acquisition of Biomet in a transaction valued at USD 14 billion, leading to its renaming as Zimmer Biomet Holdings, Inc. Geographically, the company has a presence in three regions: America, EMEA, and Asia Pacific.

• SMITH & NEPHEW PLC - The company is involved in the development, manufacturing, marketing, and sale of medical devices. It specializes in products for orthopedic reconstruction, advanced wound management, trauma & extremities, and sports medicine. Its diverse product portfolio includes knee implants, hip implants, arthroscopic enabling technologies, and more. The company utilizes a global sales force and third-party sellers to manage its sales operations. Its customer base includes surgeons, nurses, physicians, healthcare systems, procurement groups, payers, retailers, etc. In 2006, the company formed a strategic alliance with Q MED AB to handle the sales and distribution of DUROLANE and other orthopedic products.

• FERRING PHARMACEUTICAL B.V. - Ferring Pharmaceuticals B.V. is a biopharmaceutical company that specializes in researching innovative and personalized healthcare solutions. The company's primary focus is on developing and marketing pharmaceutical products to treat life-threatening conditions. Ferring offers a wide range of products in various therapeutic areas, including reproductive medicine and maternal health, gastroenterology, urology and uro-oncology, endocrinology, and orthopedics. With its expertise in assisted reproductive technology, Ferring is a leading provider of fertility treatment solutions. Additionally, the company provides peptide-based medicines to prevent preterm labor. Ferring has a global presence, operating in over 110 countries and having subsidiaries in nearly 60 countries. Its key therapeutic areas encompass reproductive health, urology, gastroenterology, and endocrinology.

• LIFECORE BIOMEDICAL, LLC (LANDEC) - Lifecore Biomedical, a subsidiary of Landec Corporation, is a fully integrated contract development and manufacturing organization that specializes in providing specialty formulation, fermentation, aseptic filling, and final packaging of FDA-regulated pharmaceuticals and medical devices. They are recognized as a significant supplier of viscoelastic and HA to the leading companies in the global ophthalmic market. Lifecore Biomedical, LLC manufactures HA and HA-based biomaterials and other non-HA-based products. They offer research-grade sodium hyaluronate and sodium hyaluronate for clinical use, along with services such as contract fermentation, aseptic filling, and the design and development of formulations, fillings, and packaging. In 2008, the company was acquired by Warburg Pincus for USD 239 million. The dental division was aligned with Warburg Pincus' product portfolio, while the hyaluronan division was transferred to Landec Corporation in 2010 for USD 40 million.

• LG LIFE SCIENCES LTD. -  Initially, LG Life Sciences Ltd. operated as a research-focused entity, but it subsequently transformed into a manufacturer of pharmaceuticals and fine chemicals. With a presence in India and Korea, the company excels in diverse areas, such as therapeutic products, animal health products, and specialty chemicals. LG Life Sciences Ltd. possesses its distribution channels to facilitate the exportation of its products to international markets. Furthermore, the company boasts functional units dedicated to research and development, production, sales, and marketing. These units collaborate to offer a wide range of products encompassing fertility treatment, hormonal therapy, veterinary medicine, viscosupplements, and other hyaluronic acid-based products.

• FIDIA FARMACEUTICI S.P.A - Fidia Farmaceutici S.p.A is engaged in the production and distribution of various products in the fields of wound care, joint health, aesthetics, neuroscience, and other areas. It is a subsidiary of the P&R Holding group, focusing on research and development, manufacturing, and marketing of pharmaceutical products. The company operates in regions such as the Americas, Asia Pacific, Europe, and MENA, utilizing a network of alliances and distributors. With a portfolio of over 600 patents, Fidia Farmaceutici sells its products in more than 100 countries. Additionally, the company has established three international subsidiaries and maintains a presence in countries like Spain, Germany, the U.S., Russia, and the Middle East through liaison offices and local businesses.

• F.HOFFMANN-LA ROCHE LTD. - The company is actively involved in the pharmaceuticals, tissue-based, and in vitro diagnostics industries and is also making a name for itself in diabetes management. Its focus on innovation in pharmaceuticals is centered around the development of targeted therapies for immuno-oncology, cardiovascular, infectious, ophthalmologic, and CNS diseases. Since entering the market, the company has successfully expanded its operations to 100 countries. The company's growth strategies primarily revolve around its research and development efforts, as evidenced by its substantial investment of USD 9.7 billion in R&D in 2015, which reflects its expanding pipeline. In 1995, the company entered into an agreement with Biomatrix to acquire the European marketing rights for Synvisc-one, a product used to treat knee osteoarthritis. As a subsidiary of Roche Holding AG, the company operates under its umbrella.

Value chain-based sizing & forecasting

Supply Side Estimates

• Company revenue estimation via referring to annual reports, investor presentations, and Hoover’s.

• Segment revenue determination via variable analysis and penetration modeling.

• Competitive benchmarking to identify market leaders and their collective revenue shares.

• Forecasting via analyzing commercialization rates, pipelines, market initiatives, distribution networks, etc.

Demand side estimates

• Identifying parent markets and ancillary markets

• Segment penetration analysis to obtain pertinent

• revenue/volume

• Heuristic forecasting with the help of subject matter experts

• Forecasting via variable analysis

Viscosupplementation Market Report Objectives:

• Understanding market dynamics (in terms of drivers, restraints, & opportunities) in the countries.

• Understanding trends & variables in the individual countries & their impact on growth and using analytical tools to provide high-level insights into the market dynamics and the associated growth pattern.

• Understanding market estimates and forecasts (with the base year as 2022, historic information from 2018 to 2021, and forecast from 2023 to 2030). Regional estimates & forecasts for each category are available and are summed up to form the global market estimates.

Viscosupplementation Market Report Assumptions:

• The report provides market value for the base year 2022 and a yearly forecast till 2030 in terms of revenue/volume or both. The market for each of the segment outlooks has been provided on region & country basis for the above-mentioned forecast period.

• The key industry dynamics, major technological trends, and application markets are evaluated to understand their impact on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis.

• We have used the bottom-up approach for market sizing, analyzing key regional markets, dynamics, & trends for various products and end-users. The total market has been estimated by integrating the country markets.

• All market estimates and forecasts have been validated through primary interviews with the key industry participants.

• Inflation has not been accounted for to estimate and forecast the market.

• Numbers may not add up due to rounding off.

• Europe consists of EU-8, Central & Eastern Europe, along with the Commonwealth of Independent States (CIS).

• Asia Pacific includes South Asia, East Asia, Southeast Asia, and Oceania (Australia & New Zealand).

• Latin America includes Central American countries and the South American continent

• Middle East includes Western Asia (as assigned by the UN Statistics Division) and the African continent.

Primary Research

GVR strives to procure the latest and unique information for reports directly from industry experts, which gives it a competitive edge. Quality is of utmost importance to us, therefore every year we focus on increasing our experts’ panel. Primary interviews are one of the critical steps in identifying recent market trends and scenarios. This process enables us to justify and validate our market estimates and forecasts to our clients. With more than 8,000 reports in our database, we have connected with some key opinion leaders across various domains, including healthcare, technology, consumer goods, and the chemical sector. Our process starts with identifying the right platform for a particular type of report, i.e., emails, LinkedIn, seminars, or telephonic conversation, as every report is unique and requires a differentiated approach.

We send out questionnaires to different experts from various regions/ countries, which is dependent on the following factors:

• Report/Market scope: If the market study is global, we send questionnaires to industry experts across various regions, including North America, Europe, Asia Pacific, Latin America, and MEA.

• Market Penetration: If the market is driven by technological advancements, population density, disease prevalence, or other factors, we identify experts and send out questionnaires based on region or country dominance.

The time to start receiving responses from industry experts varies based on how niche or well-penetrated the market is. Our reports include a detailed chapter on the KoL opinion section, which helps our clients understand the perspective of experts already in the market space.